You are here:


AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com

Cooperation Opportunities


Using the filter below you can find products potentially available for out-licensing in specific countries, including current regulatory status. You are welcome to express your interest by sending a message to our dedicated team at partnering(at)aoporphan.com.

Austria
Miltefosine optical solution
Regulatory Status: not approved
Belgium
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Bulgaria
Miltefosine optical solution
Regulatory Status: not approved
Croatia
Miltefosine optical solution
Regulatory Status: not approved
Cyprus
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Czech Republic
Miltefosine optical solution
Regulatory Status: not approved
Denmark
Miltefosine optical solution
Regulatory Status: not approved
Estonia
Miltefosine optical solution
Regulatory Status: not approved
Finland
Miltefosine optical solution
Regulatory Status: not approved
France
Miltefosine optical solution
Regulatory Status: not approved
Germany
Miltefosine optical solution
Regulatory Status: not approved
Greece
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved
Hungary
Miltefosine optical solution
Regulatory Status: not approved
Ireland
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved
Italy
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved
Latvia
Miltefosine optical solution
Regulatory Status: not approved
Lithuania
Miltefosine optical solution
Regulatory Status: not approved
Luxembourg
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Malta
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Netherlands
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Poland
Miltefosine optical solution
Regulatory Status: not approved
Portugal
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Romania
Miltefosine optical solution
Regulatory Status: not approved
Slovakia
Miltefosine optical solution
Regulatory Status: not approved
Slovenia
Miltefosine optical solution
Regulatory Status: not approved
Spain
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved
Sweden
Miltefosine optical solution
Regulatory Status: not approved
United Kingdom
Miltefosine optical solution
Regulatory Status: not approved
Bosnia-Hercegovina
Miltefosine optical solution
Regulatory Status: not approved
Macedonia
Miltefosine optical solution
Regulatory Status: not approved
Norway
Miltefosine optical solution
Regulatory Status: not approved
Serbia
Miltefosine optical solution
Regulatory Status: not approved
Switzerland
Miltefosine optical solution
Regulatory Status: not approved
Canada
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Mexico
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
USA
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Kazakhstan
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved
Russia
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Miltefosine optical solution
Regulatory Status: not approved
Ukraine
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: not approved
Landiolol 600 mg lyophilisate
Regulatory Status: not approved
Landiolol 300 mg lyophilisate
Regulatory Status: not approved
Anagrelide 2,0 mg retard tablet
Regulatory Status: not approved
Anagrelide 0,5 mg capsule
Regulatory Status: not approved
Nabilone 1 mg capsule
Regulatory Status: not approved
Nabilone 0,25 mg capsule
Regulatory Status: not approved
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: not approved